AnnouncementFebruary 25, 2026

Announcement of Business Unit Reorganization in the Diagnostics & Life Sciences Domain

PHC Group announces a reorganization of the business units (hereafter BU) in our Diagnostics & Life Sciences Domain, effective April 1, 2026.

Diagnostics & Life Sciences Domain currently consists of three BUs: the Pathology BU, the Biomedical BU, and the IVD BU. PHC Group will integrate the Biomedical BU and the IVD BU into a single BU called the “Life Sciences BU,” effective April 1, 2026, to support further growth of the domain.

Since the launch of our “Value Creation Plan 2027” (VCP) in 2024, PHC Group has been implementing initiatives to achieve our vision: “Be a leader in precision technology that powers the future of healthcare.” The reorganization announced today will further strengthen our business foundation across areas such as sales, manufacturing, and operations by maximizing efficiency and optimizing overlapping functions, more effectively utilizing the resources of the two BUs, based on one of the key initiatives of the VCP: “Focus on Diagnostics & Life Sciences.”

Chikara Takauo, the current Head of the Biomedical BU will assume leadership of the newly established Life Sciences BU. Through this integration, we aim to strengthen collaboration with the Pathology BU on a global scale and further reinforce our shared business foundation. Additionally, we will promote the development of a framework for business expansion in high-growth areas, including the field of Cell and Gene Therapy (CGT).

PHCbi will continue as a product brand.